Table 2.

Reported number and rate of toxicity (Common Terminology Criteria for Adverse Events version 4) seen in patients receiving salvage SRS for recurrent WHO Grade 3 or 4 glioma who did or did not receive bevacizumab (BVZ)

	Total	−BVZ	+BVZ
Number of patients	63	21	42
Toxicity (%)
Grade 2	20 (32)	7 (33)	13 (31)
Grade 3	7 (11)	3 (14)	4 (10)
Grade 4	1 (2)	1 (5)	0 (0)
Radionecrosis	6 (10)	4 (19)	2 (5)
Worsening of neurologic symptoms	16 (25)	6 (29)	10 (24)
Increase in seizure activity	13 (21)	4 (19)	9 (21)
Fatigue	4 (6)	0 (0)	4 (10)
Changes in memory	4 (6)	1 (5)	3 (7)
Headache	4 (6)	2 (10)	2 (5)

Abbreviations: SRS = stereotactic radiosurgery; WHO = World Health Organization; BVZ = bevacizumab.